Skip to Main Content

Mind Medicine (MindMed) Inc. Common Shares

MNMD Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of MNMD by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
MNMD Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
MNMD Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
MNMD Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by MNMD's directors and management

Government lobbying spending instances

  • $100,000 Apr 21, 2025 Issue: Health Issues
  • $60,000 Jan 17, 2025 Issue: Health Issues
  • $15,000 Oct 31, 2024 Issue: Pharmacy
  • $15,000 Oct 31, 2024 Issue: None
  • $15,000 Oct 31, 2024 Issue: None
  • $30,000 Sep 17, 2024 Issue: Health Issues
  • $30,000 Jan 22, 2024 Issue: Health Issues
  • $30,000 Jul 19, 2023 Issue: Health Issues

Estimated quarterly lobbying spending

MNMD Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
MNMD Income Statement
MNMD Balance Sheet
MNMD Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Formulations of psilocin that have enhanced stability Sep. 24, 2024
  • Patent Title: Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications Jul. 16, 2024
  • Patent Title: Synthesis routes to access mdma prodrugs by using controlled and non-controlled intermediates Feb. 13, 2024
  • Patent Title: 18-mc for treatment of substance use disorders Mar. 07, 2023
  • Patent Title: System and method for patient monitoring of gastrointestinal function using automated stool classifications Dec. 20, 2022
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
MNMD News

Recent insights relating to MNMD

CNBC Recommendations

Recent picks made for MNMD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MNMD

MNMD Analyst Ratings

MNMD Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
MNMD Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $MNMD stock a Buy, Sell, or Hold?

  • What is the price target for $MNMD stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

MNMD Top Shareholders
Shareholder
Shares Held
MNMD Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $MNMD stock?

  • Who owns the most shares of $MNMD stock?

  • What funds own $MNMD stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

MNMD Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view MNMD Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top